{
    "ticker": "ABSI",
    "name": "Absci Corporation",
    "description": "Absci Corporation is a biotechnology company that specializes in the development of therapeutic proteins through its proprietary protein expression platform. Established in 2020, Absci aims to revolutionize drug discovery and development by leveraging its advanced artificial intelligence and machine learning technologies to optimize the design of proteins for various therapeutic applications. The company focuses on generating high-quality, complex proteins that can be utilized in the creation of next-generation biologics, including monoclonal antibodies and other protein-based therapeutics. Absci's innovative approach not only accelerates the drug development process but also enhances the efficacy and safety of therapeutic candidates. The company collaborates with leading pharmaceutical and biotechnology firms to advance their drug discovery initiatives, thereby contributing to the transformation of healthcare. Absci is dedicated to improving patient outcomes by harnessing the power of synthetic biology and AI, aiming to make significant advancements in the treatment of various diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, Washington, USA",
    "founded": "2020",
    "website": "https://www.abscibio.com",
    "ceo": "Sean McClain",
    "social_media": {
        "twitter": "https://twitter.com/AbsciCorp",
        "linkedin": "https://www.linkedin.com/company/abscicorp/"
    },
    "investor_relations": "https://ir.abscibio.com",
    "key_executives": [
        {
            "name": "Sean McClain",
            "position": "CEO"
        },
        {
            "name": "Angela G. Hwang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Proteins",
            "products": [
                "Monoclonal Antibodies",
                "Protein-based Therapeutics"
            ]
        },
        {
            "category": "Biotechnology Platforms",
            "products": [
                "Protein Expression Platform",
                "AI-Driven Drug Discovery"
            ]
        }
    ],
    "seo": {
        "meta_title": "Absci Corporation | Biotechnology and Therapeutic Proteins",
        "meta_description": "Learn about Absci Corporation, a leader in biotechnology focused on therapeutic proteins and AI-driven drug discovery. Explore our innovative platforms and solutions.",
        "keywords": [
            "Absci",
            "Biotechnology",
            "Therapeutic Proteins",
            "Drug Discovery",
            "Synthetic Biology",
            "AI in Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What is Absci known for?",
            "answer": "Absci is known for its advanced biotechnology platform that develops therapeutic proteins using AI and machine learning."
        },
        {
            "question": "Who is the CEO of Absci?",
            "answer": "Sean McClain is the CEO of Absci Corporation."
        },
        {
            "question": "Where is Absci headquartered?",
            "answer": "Absci is headquartered in Vancouver, Washington, USA."
        },
        {
            "question": "What are Absci's main products?",
            "answer": "Absci's main products include monoclonal antibodies and protein-based therapeutics developed through its proprietary platform."
        },
        {
            "question": "When was Absci founded?",
            "answer": "Absci was founded in 2020."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "MRNA"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "NVDA",
        "GILD"
    ]
}